Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti ® (cipaglucosidase alfa) + Opfolda ® (miglustat) as Best Pharmaceutical Product

Tuesday, 4 June 2024, 08:16

Amicus Therapeutics has been honored with the esteemed Prix Galien U.K. Award for their exceptional pharmaceutical product, Pombiliti ® (cipaglucosidase alfa) + Opfolda ® (miglustat). This recognition highlights their commitment to innovation and excellence in the healthcare industry. The award signifies the high regard for the quality and impact of Amicus Therapeutics' products in the market.

https://store.livarava.com/ae8c13c7-2264-11ef-a3fe-9d5fa15a64d8.jpg — Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti ® (cipaglucosidase alfa) + Opfolda ® (miglustat) as Best Pharmaceutical Product

Amicus Therapeutics Receives Prix Galien U.K. Award

Amicus Therapeutics has been recognized with the prestigious Prix Galien U.K. Award for their outstanding pharmaceutical product, Pombiliti ® (cipaglucosidase alfa) + Opfolda ® (miglustat).

Acknowledgment of Excellence

The award underscores Amicus Therapeutics' dedication to developing innovative and high-quality healthcare solutions for patients.

The accolade serves as a testament to the company's commitment to driving advancements in the pharmaceutical industry.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.